NCT05596097View on ClinicalTrials.gov

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

October 20, 2024

Study Completion Date

July 30, 2026

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG

Zanubrutinib

Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days

Trial Locations (1)

730000

The First Hospital of Lanzhou University, Lanzhou

Sponsors

Collaborators (1)

BeOne Medicines

All Listed Sponsors

collaborator

BeOne Medicines

INDUSTRY

lead

LanZhou University

OTHER

NCT05596097 - Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | Biotech Hunter | Biotech Hunter